EP0763202A1 - Encoded combinatorial libraries - Google Patents
Encoded combinatorial librariesInfo
- Publication number
- EP0763202A1 EP0763202A1 EP95920576A EP95920576A EP0763202A1 EP 0763202 A1 EP0763202 A1 EP 0763202A1 EP 95920576 A EP95920576 A EP 95920576A EP 95920576 A EP95920576 A EP 95920576A EP 0763202 A1 EP0763202 A1 EP 0763202A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- beads
- library
- reaction
- combinatorial
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011324 bead Substances 0.000 claims abstract description 148
- 238000000034 method Methods 0.000 claims abstract description 106
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 238000000684 flow cytometry Methods 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims description 143
- 238000012360 testing method Methods 0.000 claims description 44
- 239000007850 fluorescent dye Substances 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 description 41
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 34
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 34
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 30
- 239000000178 monomer Substances 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 17
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 14
- 230000004071 biological effect Effects 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 10
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 9
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002019 doping agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 238000005556 structure-activity relationship Methods 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- PIPTUBPKYFRLCP-NHCYSSNCSA-N Ala-Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PIPTUBPKYFRLCP-NHCYSSNCSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- MZMNEDXVUJLQAF-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CC(O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-UHFFFAOYSA-N 0.000 description 3
- BFHRKLXYYTUWFT-UHFFFAOYSA-N 4-perylen-1-ylbutanoic acid Chemical compound C1=CC(C=2C(CCCC(=O)O)=CC=C3C=2C2=CC=C3)=C3C2=CC=CC3=C1 BFHRKLXYYTUWFT-UHFFFAOYSA-N 0.000 description 3
- QXYRRCOJHNZVDJ-UHFFFAOYSA-N 4-pyren-1-ylbutanoic acid Chemical compound C1=C2C(CCCC(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 QXYRRCOJHNZVDJ-UHFFFAOYSA-N 0.000 description 3
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 3
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 3
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 3
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 3
- QHASENCZLDHBGX-ONGXEEELSA-N Ala-Gly-Phe Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QHASENCZLDHBGX-ONGXEEELSA-N 0.000 description 3
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 3
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 3
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 3
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 3
- MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 3
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 3
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 3
- WMGHDYWNHNLGBV-ONGXEEELSA-N Gly-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WMGHDYWNHNLGBV-ONGXEEELSA-N 0.000 description 3
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 description 3
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 3
- FPTXMUIBLMGTQH-ONGXEEELSA-N Phe-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 3
- LBSARGIQACMGDF-WBAXXEDZSA-N Phe-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 LBSARGIQACMGDF-WBAXXEDZSA-N 0.000 description 3
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 3
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 3
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 3
- CBENHWCORLVGEQ-HJOGWXRNSA-N Phe-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CBENHWCORLVGEQ-HJOGWXRNSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 description 3
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 3
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 3
- 108010065135 phenylalanyl-phenylalanyl-phenylalanine Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 3
- JAQNUEWEJWBVAY-WBAXXEDZSA-N Ala-Phe-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 JAQNUEWEJWBVAY-WBAXXEDZSA-N 0.000 description 2
- 241001156002 Anthonomus pomorum Species 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 description 2
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- -1 benzylic halides Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- LTTGTYFPOUSRID-KEKNWZKVSA-N (2s)-6-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-7-[(2-methylpropan-2-yl)oxy]-7-oxoheptanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC(N)C(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 LTTGTYFPOUSRID-KEKNWZKVSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001795 coordination polymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00572—Chemical means
- B01J2219/00576—Chemical means fluorophore
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00592—Split-and-pool, mix-and-divide processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Definitions
- the field of this invention concerns combinatorial chemistry which involves the syntheses of one or more encoded combinatorial libraries where large numbers of products having varying compositions are obtained. This invention also relates to methods of encoding combinatorial libraries.
- the standard method for conducting a search is to screen a variety of pre-existing chemical moieties, for example, naturally occurring compounds or compounds which exist in synthetic libraries or databanks.
- the biological activity of the pre-existing chemical moieties is determined by applying the moieties to an assay which has been designed to test a particular property of the chemical moiety being screened, for example, a receptor binding assay which tests the ability of the moiety to bind to a particular receptor site.
- Nonpeptidic organic compounds such as peptide mimetics
- peptide mimetics can often surpass peptide ligands in affinity for a certain receptor of enzyme.
- An effective strategy for rapidly identifying high affinity biological ligands, and ultimately new and important drugs, requires rapid construction and screening of diverse libraries of non-peptidic structures containing a variety of structural units capable of establishing one or more types of interactions with a biological acceptor (e.g., a receptor or enzyme), such as hydrogen bonds, salt bridges, pi-complexation, hydrophobic effects, etc.
- a biological acceptor e.g., a receptor or enzyme
- a key unsolved problem in the area of generation and use of nonpeptide libraries is the generation and use of nonpeptide libraries is the elucidation of the structure of molecules selected from a library that show promising biological activity.
- An attempt to uncover the structures of peptides selected from a library using unique nucleotide sequence codes, which are synthesized in tandem with the peptide library, has been described by Brenner and Lerner (Brenner, S. and Lerner, R.A. Pmc. Nat'l. Acad. Sci. USA. 1992 89 . 5381-5383).
- the nucleotide sequence of the code attached to each peptide must be amplifiable via the polymerase chain reaction (PCR).
- nucleotide synthesis techniques are not compatible with all of the synthetic techniques required for synthesis of many types of molecular libraries.
- the close proximity of nucleotide and synthetic test compound in the library which can result in interactions between these molecules interfering with the binding of the ligand with a target receptor of enzyme during the biological assay, also limits this approach.
- the nucleotide component of the library can also interfere during biological assays in a variety of other ways.
- PCT/HU93/0030 describes fluorescently labeled sub-library peptide kits for use in peptide synthesis.
- PCT/US94 06078 describes methods of encoding combinatorial libraries using polymeric sequences.
- This invention relates to a method for identifying compounds having desired characteristics and identifying essential moieties in a lead structure which comprises preparing one or more encoded combinatorial libraries from a specified set of reaction sequences and testing compounds therein for biological activity.
- This invention also relates to a method of encoding a single registry in each combinatorial library of a series of combinatorial libraries and combinatorial libraries with a single encoded registry.
- This invention also relates to a method of encoding combinatorial libraries which comprises utilization of tagged beads.
- This invention also relates to a method of encoding each choice of a combinatorial library and combinatorial libraries encoded thereby.
- This invention also relates to beads with fluorescently labeled identifiers attached thereto.
- the term "beads” means any solid support material capable of providing a base for combinatorial syntheses and capable of being processed by flow cytometry, such as 1 to 2% crosslinked polystyrene, polyacrylamide, polyethylene glycol polystyrene co-polymer, preferably Tentagel 10 to 100 micron particles, most preferably Tentagel 10-30 micron particles.
- sort means to form beads into groups which have a common tagging aspect by flow cytometry.
- the term "separate” or “split” when referring to encoded beads or beads of a combinatorial library means to partition the mixture of beads into groups, each group thereinby containing a mixture, preferably a statistical mean of all members.
- the term "tag”, unless otherwise indicated, means an encoding characteristic of a bead or group of beads which is capable of being sorted by flow cytometry, such as differences in size, differences in material composition, differences in flow properties, a single fluorescent marker or, preferably, a fluorescent label identifier.
- fluorescent label identifier or "identifier” means a coding label attached to a bead or group of beads either by adding ratios of a fluorophore and a non-fluorophore or by adding multiple, preferably two, different fluorophores in varying ratios.
- the term "intensity-differentiated” means an identifier (as used herein) in which varying ratios of a fluorophore and a non-fluorophore are added to a bead or group of beads.
- the term “choice” means the alternative variables for a given stage in a combinatorial synthesis (not limited to peptide chemistry), such as reactant, reagent, reaction conditions, and combinations thereof.
- stage corresponds to a step in the sequential synthesis of a compound or ligand; the compound or ligand being the final product of a combinatorial synthesis.
- registration as used herein, has the same meaning as the term "stage” as indicated above.
- a series of combinatorial libraries are prepared, each individual library being prepared from substantially the same specified set of reaction sequences, therein encoding a single registry within each combinatorial library and analyzing according to mixtures of compounds with a homogeneous registry.
- the specific encoded registry of any library will be different from the other libraries and the number of libraries prepared will equal the number of registries in a single library.
- the number of readily identifiable groups of beads will correspond to the number of choices in the first registry, the entirety of each group is entered into a separate container.
- the beads will usually be divided up into groups of at least one bead each, usually a plurality of beads, generally 1000 or more, and may be 10 ⁇ or more depending on the total number of registries involved in the library.
- stages or "registries” as used herein.
- the procedure of dividing beads, followed by a synthetic stage (to form a registry), and then recombining beads is iterated until the first combinatorial library is completed.
- the same reaction may be carried out in 2 or more containers to enhance the proportion of product having a particular reaction in a particular registry as compared to the other choices.
- one or more of the registries may involve a portion of the beads being set aside and undergoing no reaction, so as to enhance the variability associated with the final product.
- batches may be taken along different synthetic pathways. The library thus prepared will contain tagged beads which identify the reaction sequence of the first registry only.
- a combinatorial library containing tagged beads which identify the reaction sequence of the first registry only can be prepared as outlined in Scheme 1 below.
- Scheme 1 outlines the preparation of a combinatorial library in which only the first registry has been encoded.
- beads with attached fluorescently labeled identifiers are derivatized with a linker that allows for cleavage of the compound to be tested.
- each group of similarly tagged beads is entered into a separate container and subjected to specified reaction conditions (or variable building blocks, as used herein) to form the first registry.
- specified reaction conditions or variable building blocks, as used herein
- the beads may be tagged in a similar manner as in the first library.
- the beads for use in the second library are first combined into a single mixture and then separated according to the number of choices for the first registry.
- the synthetic schemeSchoices for each registry of the second library and all subsequent libraries will be substantially the same as the synthetic schemeSchoices of the corresponding registry in the first library.
- this combination of beads will be sorted using flow cytometry.
- each group of similarly tagged beads is entered into a separate container and subjected to the same synthetic scheme(s) ⁇ choice(s) used for the second registry of the first library.
- the reaction(s) is complete, one may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then separating the beads according to the number choices in the third registry of the first library. This procedure of dividing beads, followed by the synthetic scheme(s) ⁇ choice(s) from the corresponding registry of the first library, and then recombining the beads is iterated until the second library in completed.
- the library thus prepared will contain tagged beads which identify the reaction sequence of the second registry only.
- a combinatorial library containing tagged beads which identify the reaction sequence of the second registry only can be prepared as outlined in Scheme 2 below.
- Scheme 2 outlines the preparation of a combinatorial library in which only the second registry has been encoded.
- beads with attached fluorescent label identifiers are first combined into a single mixture and then separated into groups according to the number of choices in the first registry of the first library . Subsequently, each group is entered into a separate container and subjected to the same reaction conditions of the first registry of the first library to form the first registry of the second library. Once the reaction(s) is complete the beads are combined into a single mixture and then sorted into groups according to similarly tagged beads. Preferably this combination of beads will be sorted using flow cytometry.
- Each group of similarly tagged beads is entered into a separate container and subjected to the same reaction conditions of the second registry of the first library to form the second registry of the second library.
- the beads are combined into a single mixture and then separated according to the number of choices in the third registry of the first library and reacted accordingly.
- This procedure of dividing the beads, fol a d by subjection to specified reaction conditions from the corresponding r-. of the first library, and then recombining the beads is iterated until the second horary is completed.
- the completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous second registry is obtained from this library.
- the above process is repeated to prepare subsequent libraries (when desired), provided that the sorting procedure is performed prior to a different synthetic stage in each library.
- the combinatorial libraries thus prepared will contain tagged beads which identify the reaction sequence of a single registry only. Further, the identifiableSencoded registry in each combinatorial library will be different.
- each library is tested separately for biological activity.
- testing for biological activity or “testing for desired characteristics” as used herein includes any form of testing for pharmaceutical activity including the methods indicated below.
- the compounds of a library may be tested on the beads, for example by bio-panning using a soluble receptor assay, and the activities analyzed preferably by flow cytometry.
- the contents of the library may be sorted preferably by flow cytometry and the compounds tested on the beads, or the sorted compounds cleaved from the beads prior to testing.
- Analysis of the first combinatorial library will yield the SAR of variable building block A.
- Analysis of the second combinatorial library will yield the SAR of variable building block B.
- Analysis of the third combinatorial library will yield the SAR of variable building block C.
- Analysis of the S ARs of the three variable building blocks (A, B and C) will identify desired reaction sequences and suggest multiple lead structures.
- fluorescent label identifiers when referring to fluorophore labeled beads means: i) that all of the beads in a given pool will have the same fluorescence intensity and different pools will have intensities that differ from any other pool by a factor of at least 2, preferably 3 or more or ii) that multiple, preferably 2, different fluorescent tags are used in varying ratios such that all of the beads in a given pool will have the same combination of fluorescent tags in the same ratio and different pools will have: a) the same fluorescent tags but in ratios that differ from any other pool, b) a different set of fluorescent tags in a specified ratio or c) a combination of a) and b).
- flow cytometers are able to sort beads that differ in fluorescence intensity by a factor of 2.
- the principles of flow cytometry and general methods for using flow cytometry are described in Grogan and Collins, Guide to Flow Cytometry Methods. Pub: Marcel Dekker, Inc. (1990).
- Intensity-differentiated fluorophore-labeled beads can be prepared by derivatizing pools of beads with varying amounts of a fluorophore and a non- fluorophore or by varying the reaction time of a single reactive fluorescent tag. Additionally, multiple, preferably 2, fluorescent tags can be used in varying ratios to encoded beads.
- A first fluorescent tag
- B second fluorescent tag
- intensity-differentiated fluorophore-labeled beads can be prepared by the method outlined in Scheme 3 below and in the Examples.
- R is a fluorescent tag T* or a doping agent
- D and R' is a fluorescent tagT ⁇ or a doping agent D, provided that when R is D, R' is other that D.
- a sample of beads is derivatized with a linker, preferably ⁇ -Boc-FMOC lysine, by standard coupling chemistry.
- a linker preferably ⁇ -Boc-FMOC lysine
- a benzyl alcohol linker such as used with the Wang linker or a benzyl halide linker such as used with the Merrifield linker, or a benzhydryl amine linker as used with the Rink linker can be attached to the beads by the formation of ethers by alkylation of alcohols, alkylation or arylation by Friedl Crafts chemistry, the formation of biaryls by palladium mediated cross-coupling chemistry or by standard amide coupling chemistry.
- a mono- deprotection step such as 20% piperdine/ DMF, for removal of an FMOC is performed.
- the beads are then divided into N pools.
- Pool 1 is derivatized with a fluorophore, such as pyrene butyric acid.
- Pool 2 is derivatized with a 1:3 mixture of a fluorophore, such as pyrene butyric acid, and a non-fluorophore (hereinafter a "doping agent"), such as butyric acid or a different fluorophore, such as perylene butyric acid.
- a fluorophore such as pyrene butyric acid
- a non-fluorophore hereinafter a "doping agent”
- Pool N is derivatized with a 1: 3( ⁇ -1) ratio of a fluorophore, such as pyrene butyric acid, and a doping agent, such as butyric acid or a different fluorophore, such as perylene butyric acid.
- a fluorophore such as pyrene butyric acid
- a doping agent such as butyric acid or a different fluorophore, such as perylene butyric acid.
- Each of these pools of beads can be differentiated from any other pool of beads by flow cytometry.
- Each pool of beads may also be differentiated from one another by inspection with the unaided eye, however fewer variables could be encoded this way.
- different fluorophores with different absorption and emittance wavelengths and multiple fluorophores could be encoded by fluorescence quenching to encode additional variables.
- the use of multiple fluorophores, the ratio of which is the identifier, has several advantages including the ability to greatly increases the number of variables that can be identified by using the same number of tags and enabling analysis independent of bead size. Also, the same strategy can be applied to prepare beads that can be used to discriminate between library members with redundant molecular weights by fluorescence, preferably by starting with beads with at least 50 pmoles of linker.
- a single combinatorial library is prepared, each choice therein being encoded by a tag, preferably using fluorescent label identifiers, and tested for biological activity, preferably without mixing the final pools.
- the “Combine and Split protocol” is utilized to synthesize encoded beads, preferably with fluorescent label identifiers attached thereto.
- the “Combine and Split protocol” is advantageous in that it eliminates the need to resynthesize, or parallel synthesize, libraries containing only one or two fluorescent tags. This aspect of the invention is especially attractive from a practical point of view since the encoded beads can be prepared in bulk, prior to the actual synthesis of combinatorial libraries.
- An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspect of this invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspect -his invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
- STEP 6 Combine and sort by T x j*>.
- P ⁇ is encoded by T ⁇ n
- Scheme 4 outlines the preparation of a combinatorial library in which each choice therein is encoded by a unique identifier.
- untagged beads are encoded with the first identifier (as described in Scheme 3).
- the encoded beads are combined into a single mixture and then separated into groups according to the number of permutations of the second identifier.
- the beads are then encoded with the second identifier. (The above encoding process is repeated until groups of encoded beads of desired size is obtained).
- the beads encoded with the second identifier are combined into a single mixture and then separated into groups according to the number of permutations of the third identifier.
- the beads are then encoded with the third identifier.
- Encoded beads prepared according to the above methods and said methods represent preferred embodiments of the claimed invention.
- the beads thus prepared are maintained in separate homogeneous pools of like identifiers according to the third identifier and subjected to the first stage (or registry as used herein) of specified reaction conditions.
- the choices of the first registry are thereinby encoded by the third identifier.
- the beads are then combined and sorted, preferably by flow cytometry, into homogeneous pools of like identifiers according to the first identifier.
- the beads thus obtained are maintained in separate pools and subjected to the second stage of specified reaction conditions.
- the choices of the second registry are thereinby encoded by the first identifier.
- the beads are then combined and sorted, preferably by flow cytometry, into homogeneous pools of like identifiers according to the second identifier.
- the beads thus obtained are maintained in separate pools and subjected to the third stage of specified reaction conditions.
- the choices of the third registry are thereinby encoded by the second identifier.
- the beads are then combined and separated into groups according to the number of choices of the forth stage and subjected to the forth stage of specified reaction conditions.
- the pools of beads thus obtained are maintained in these separate groups and tested for biological activity.
- the choices of the forth registry are thereinby separately maintained.
- each of these groups are separately tested for biological activity and analyzed, preferably by flow cytometry or by cleavage of compounds from individual groups or from smaller sets of individual groups.
- the exact reaction history of each active can be identified by reading the unique identifier from the corresponding bead.
- a bifunctional linker such as e-Boc-FMOC-L- lysine (8.4 g, 6 eq., 18 mmol, Novabiochem), an amide coupling agent such as diisopropyl carbodiimide ( 2.3 g, 2.8 ml, 6 eq., 18 mmol, Aldrich) is added to Polyethylene glycol-linked to cross-linked polystyrene beads (Tentagel M NH2, 10 micron particle size, 15.0 g, 3 mmol, Rapp Polymere) suspended in a suitable solvent such as N-methyl pyrrolidine (300 ml) and is agitated overnight The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 100 ml).
- a bifunctional linker such as e-Boc-FMOC-L- lysine (8.4 g, 6 eq., 18 mmol, Novabiochem
- an amide coupling agent
- the beads are then agitated with 25% piperidine/ DMF (300 ml) for 15 min.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 100 ml), then CH2CI2 (5 x 100 ml), then air dried.
- the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1 -pyrene butyric acid (1.7 g, 6 eq., 6 mmol, Aldrich) and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads are then agitated in 25% TFA/ CH2CI2 (100 ml) for 2 h removing the Boc protective group.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
- the beads are then re suspended in THF ( 100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
- the beads ( 5 g), as prepared in Procedure B, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Procedure ⁇ >- The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1 -pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol), and a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- a fluorophore such as 1 -pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol)
- a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichi
- reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads are then agitated in 25% TFA/ CH2CI2 (100 ml) for 2 h removing the Boc protective group.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
- the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
- Procedure E The beads ( 5 g), as prepared in Procedure D, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol). Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours. The reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- a monomer such as FMOC-L- alanine
- the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1 -pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol), and a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- a fluorophore such as 1 -pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol)
- a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoich
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH2CI2 (5 x 100 ml), then air dried.
- the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried.
- the beads ( 5 g), as prepared in Procedure F, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Procedure H The beads obtained from procedures C, E, and G are then combined and split into 3 equal portions.
- Pool HI is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool H2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Procedure I The beads obtained from Procedure H are then combined and split into 3 equal portions.
- Procedure J The beads obtained from Procedure I are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence. Sublibrary components have the same first amino acid of the tripeptide.
- Sublibrary Jl consists of Gly-X-X or Gly-Gly-Gly, Gly-Gly-Ala, Gly-Gly-Phe, Gly- Ala- Gly, Gly-Ala-Ala, Gly-Ala-Phe, Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe.
- Sublibrary J2 consists of Ala-X-X or Ala-Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Ala- Ala- Gly, Ala-Ala- Ala, Ala-Ala-Phe, Ala-Phe-Gly, Ala-Phe-Ala, Ala-Phe-Phe
- Sublibrary J3 consists of Phe-X-X or Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly-Phe, Phe- Ala- Gly, Phe-Ala-Ala, Phe-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe-Phe-Phe-Phe
- Procedure L The beads obtained from Procedure K are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
- Pool LI is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool L2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool M2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool M3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
- the beads obtained from Procedure M are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence.
- Sublibrary components have the same second amino acid of the tripeptide.
- Sublibrary Nl consists of X-Gly-X or Gly-Gly-Gly, Gly-Gly- Ala, Gly-Gly-Phe, Ala- Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly- Phe
- Sublibrary N2 consists of X-Ala-X or Gly-Ala-Gly, Gly- Ala- Ala, Gly-Ala-Phe, Ala- Ala- Gly, Ala- Ala- Ala, Ala-Ala-Phe, Phe-Ala-Gly, Phe-Ala-Ala, Phe-Ala- Phe
- Sublibrary N3 consists of X-Phe-X or Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe, Ala-Phe- Gly, Ala-Phe-Ala, Ala-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe- Phe-Phe-Phe
- Procedure O The beads (5.0 g), as described in Procedure K, are combined and split into 3 equal portions.
- Pool 03 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool P2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool P3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), the£ air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads obtained from Procedure P are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
- Pool Ql is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the re son is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 Cl2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool Q2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH2CI2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the pools of beads obtained from Procedure Q are already sorted into sublibraries in which the third amino acid of each component is the same the same amino acid of the tripeptide.
- Sublibrary Ql consists of X-X-Gly or Gly-Gly-Gly, Gly-Ala-Gly, Gly-Phe-Gly,
- Gly Sublibrary Q2 consists of X-X-Ala or Gly-Gly- Ala, Gly- Ala- Ala, Gly-Phe- Ala,
- Ala-Gly- Ala Ala- Ala- Ala, Ala-Phe-Ala, Phe-Gly-Ala, Phe-Ala-Ala, Phe-
- Sublibrary Q3 consists of X-X-Phe or Gly-Gly-Phe, Gly-Ala-Phe, Gly-Phe-Phe,
- Example 1 The methods of Example 1 are used except that the doping reagent is replaced by a second fluorophore such as perylene butyric acid.
- a second fluorophore such as perylene butyric acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24779394A | 1994-05-23 | 1994-05-23 | |
| US247793 | 1994-05-23 | ||
| US26733394A | 1994-06-28 | 1994-06-28 | |
| US267333 | 1994-06-28 | ||
| US38254295A | 1995-02-01 | 1995-02-01 | |
| US382542 | 1995-02-01 | ||
| US41043695A | 1995-03-23 | 1995-03-23 | |
| US410436 | 1995-03-23 | ||
| PCT/US1995/006392 WO1995032425A1 (en) | 1994-05-23 | 1995-05-23 | Encoded combinatorial libraries |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0763202A1 true EP0763202A1 (en) | 1997-03-19 |
| EP0763202A4 EP0763202A4 (en) | 1998-12-09 |
Family
ID=27500266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95920576A Withdrawn EP0763202A4 (en) | 1994-05-23 | 1995-05-23 | Encoded combinatorial libraries |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0763202A4 (en) |
| JP (1) | JPH10500951A (en) |
| WO (1) | WO1995032425A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7034110B2 (en) | 1994-01-05 | 2006-04-25 | Arqule, Inc. | Method of identifying chemical compounds having selected properties for a particular application |
| US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
| US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US6096496A (en) * | 1997-06-19 | 2000-08-01 | Frankel; Robert D. | Supports incorporating vertical cavity emitting lasers and tracking apparatus for use in combinatorial synthesis |
| AU8678198A (en) * | 1997-08-01 | 1999-02-22 | Novalon Pharmaceutical Corporation | Method of identifying and developing drug leads |
| EP1036332B1 (en) * | 1997-12-04 | 2005-07-13 | Amersham Biosciences UK Limited | Multiple assay method |
| US6455263B2 (en) * | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
| US6613575B1 (en) | 1998-03-27 | 2003-09-02 | Ole Hindsgaul | Methods for screening compound libraries |
| CA2240325A1 (en) | 1998-03-27 | 1998-11-14 | Synsorb Biotech, Inc. | Methods for screening compound libraries |
| US6054047A (en) | 1998-03-27 | 2000-04-25 | Synsorb Biotech, Inc. | Apparatus for screening compound libraries |
| US6720190B1 (en) | 1998-03-27 | 2004-04-13 | Ole Hindsgaul | Methods for screening compound libraries |
| CA2337490C (en) | 1998-08-17 | 2012-01-03 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
| US6642062B2 (en) * | 1998-09-03 | 2003-11-04 | Trellis Bioinformatics, Inc. | Multihued labels |
| AUPP737298A0 (en) * | 1998-11-30 | 1998-12-24 | University Of Queensland, The | Combinatorial libraries |
| JP2002541226A (en) * | 1999-04-09 | 2002-12-03 | グラクソ グループ リミテッド | Code scheme for solid-phase chemical libraries |
| EP1175505A4 (en) * | 1999-04-15 | 2005-04-20 | Vitra Bioscience Inc | Combinatorial chemical library supports having indicia at coding positions and methods of use |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| DE60118527D1 (en) | 2000-01-24 | 2006-05-18 | Compound Therapeutics Inc | SENSITIVE AND MULTIPLEXED DIAGNOSTIC TESTS FOR PROTEIN ANALYSIS |
| CN100346163C (en) * | 2000-02-07 | 2007-10-31 | 协和梅迪克斯株式会社 | Method and apparatus for detecting substance |
| WO2001080622A2 (en) * | 2000-04-26 | 2001-11-01 | Streamline Proteomics | Apparatus and methods for assays of one or more analytes |
| WO2002064829A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting genetic characteristics |
| ES2284832T3 (en) * | 2001-02-13 | 2007-11-16 | Pronostics Limited | BIOCHEMICAL PROCEDURE AND APPARATUS FOR THE DETECTION OF PROTEIN CHARACTERISTICS. |
| US20090210165A1 (en) | 2003-12-22 | 2009-08-20 | Carlsberg A/S | Identification of encoded beads |
| WO2005062018A2 (en) | 2003-12-22 | 2005-07-07 | Versamatrix A/S | Apparatus and methods for analysis and sorting of particles such as polymer beads |
| US11237171B2 (en) | 2006-02-21 | 2022-02-01 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
| US8460878B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for detecting cells and cellular components in small defined volumes |
| CA2681415C (en) | 2007-03-22 | 2020-11-03 | Heptares Therapeutics Limited | Mutant g-protein coupled receptors and methods for selecting them |
| JP5503540B2 (en) | 2007-08-30 | 2014-05-28 | トラスティーズ・オブ・タフツ・カレッジ | Method for determining analyte concentration in solution |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| US8222047B2 (en) | 2008-09-23 | 2012-07-17 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
| GB0904904D0 (en) | 2009-03-23 | 2009-05-06 | Univ Leiden Medical Ct | Angiogenesis methods, medicaments and agents |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| GB201002082D0 (en) | 2010-02-09 | 2010-03-24 | Univ Leiden Medical Ct | Biological material |
| US8415171B2 (en) | 2010-03-01 | 2013-04-09 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
| US9678068B2 (en) | 2010-03-01 | 2017-06-13 | Quanterix Corporation | Ultra-sensitive detection of molecules using dual detection methods |
| ES2544635T3 (en) | 2010-03-01 | 2015-09-02 | Quanterix Corporation | Methods to extend the dynamic range in assays for the detection of molecules or particles |
| US8236574B2 (en) | 2010-03-01 | 2012-08-07 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
| US20140030218A1 (en) | 2011-01-05 | 2014-01-30 | Imperial Innovations Limited | Treatment And Screening |
| US9952237B2 (en) | 2011-01-28 | 2018-04-24 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
| WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
| US9932626B2 (en) | 2013-01-15 | 2018-04-03 | Quanterix Corporation | Detection of DNA or RNA using single molecule arrays and other techniques |
| GB201501004D0 (en) | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| GB201814451D0 (en) | 2018-09-05 | 2018-10-17 | Valerie Nicholas Carl Kristoffer | Methods |
-
1995
- 1995-05-23 EP EP95920576A patent/EP0763202A4/en not_active Withdrawn
- 1995-05-23 WO PCT/US1995/006392 patent/WO1995032425A1/en not_active Ceased
- 1995-05-23 JP JP7530459A patent/JPH10500951A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| No further relevant documents disclosed * |
| See also references of WO9532425A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0763202A4 (en) | 1998-12-09 |
| JPH10500951A (en) | 1998-01-27 |
| WO1995032425A1 (en) | 1995-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0763202A1 (en) | Encoded combinatorial libraries | |
| US6210900B1 (en) | Method of encoding a series of combinatorial libraries and developing structure activity relationships | |
| US6416949B1 (en) | Method of synthesizing diverse collections of oligomers | |
| Lebl et al. | One‐bead–one‐structure combinatorial libraries | |
| Früchtel et al. | Organic chemistry on solid supports | |
| US5541061A (en) | Methods for screening factorial chemical libraries | |
| AU686186B2 (en) | Topologically segregated, encoded solid phase libraries | |
| Jacobs et al. | Combinatorial chemistry—applications of light-directed chemical synthesis | |
| US7338768B1 (en) | Carrier-reporter bead assemblies | |
| CA2466164A1 (en) | Device and methods for directed synthesis of chemical libraries | |
| US6168913B1 (en) | Coding combinatorial libraries with fluorine tags | |
| Schmuck et al. | The development of artificial receptors for small peptides using combinatorial approaches | |
| US20050095638A1 (en) | Factorial chemical libraries | |
| US20050100968A1 (en) | Self-encoded combinatorial synthesis of compound multiplets | |
| WO1997032892A1 (en) | A composite for combinatorial organic synthesis | |
| WO1997029371A1 (en) | Sulfur ratio tagging method for combinatorial libraries | |
| Krämer et al. | Encoding technologies | |
| AU742678B2 (en) | Carrier-reporter bead assemblies | |
| Lebl et al. | Felder zyxwvutsrqponmlkj | |
| CA2392919A1 (en) | Systems and methods to facilitate multiple order combinatorial chemical processes | |
| Wich | Springer-Verlag Berlin Heidelberg Published online: 10 March 2007 The Development of Artificial Receptors for Small Peptides Using Combinatorial Approaches Carsten Schmuck () Peter Wich | |
| CA2285175A1 (en) | Rink-chloride linker for solid phase organic synthesis of organic molecules | |
| AU2002357677A1 (en) | Device and methods for directed synthesis of chemical libraries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19961206 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19981027 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE FR GB IT LI NL |
|
| RHK1 | Main classification (correction) |
Ipc: C07K 1/04 |
|
| 17Q | First examination report despatched |
Effective date: 20001219 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030211 |